Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George R Simon

Showing results (41-50 of 77) with videos related to

Pageof 8
Sort By:
Oncoscience|January 17, 2015
Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lungNeeta Somaiah, Mary Jo Fidler, Elizabeth Garrett-Mayer, et al.
Biosensors & Bioelectronics|January 1, 2013
Multiplexed specific label-free detection of NCI-H358 lung cancer cell line lysates with silicon based photonic crystal microcavity biosensorsSwapnajit Chakravarty, Wei-Cheng Lai, Yi Zou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesotheliomaPasi A Jänne, George R Simon, Corey J Langer, et al.
Plos One|February 25, 2012
A novel classification of lung cancer into molecular subtypesLisandra West, Smruti J Vidwans, Nicholas P Campbell, et al.
JCO Clinical Cancer Informatics|December 13, 2024
Real-World and Clinical Trial Validation of a Deep Learning Radiomic Biomarker for PD-(L)1 Immune Checkpoint Inhibitor Response in Advanced Non-Small Cell Lung CancerChiharu Sako, Chong Duan, Kevin Maresca, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 3, 2013
Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinomaBen C Creelan, Scott Antonia, David Noyes, et al.
Cancer|February 27, 2008
Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or olderGeorge R Simon, Martine Extermann, Alberto Chiappori, et al.
Molecular Cancer Therapeutics|August 25, 2006
Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trialGeorge R Simon, Richard M Lush, Jana Gump, et al.
JCO Precision Oncology|May 16, 2024
Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non-Small Cell Lung CancerJeanna Wallenta Law, Bela Bapat, Connor Sweetnam, et al.
Cancer Control : Journal of the Moffitt Cancer Center|October 29, 2003
Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institutionGeorge R Simon, John C Ruckdeschel, Charles Williams, et al.
Pageof 8

Showing results (41-50 of 77) with videos related to

Sort By:
Pageof 8
Oncoscience|January 17, 2015
Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lungNeeta Somaiah, Mary Jo Fidler, Elizabeth Garrett-Mayer, et al.
Biosensors & Bioelectronics|January 1, 2013
Multiplexed specific label-free detection of NCI-H358 lung cancer cell line lysates with silicon based photonic crystal microcavity biosensorsSwapnajit Chakravarty, Wei-Cheng Lai, Yi Zou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesotheliomaPasi A Jänne, George R Simon, Corey J Langer, et al.
Plos One|February 25, 2012
A novel classification of lung cancer into molecular subtypesLisandra West, Smruti J Vidwans, Nicholas P Campbell, et al.
JCO Clinical Cancer Informatics|December 13, 2024
Real-World and Clinical Trial Validation of a Deep Learning Radiomic Biomarker for PD-(L)1 Immune Checkpoint Inhibitor Response in Advanced Non-Small Cell Lung CancerChiharu Sako, Chong Duan, Kevin Maresca, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 3, 2013
Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinomaBen C Creelan, Scott Antonia, David Noyes, et al.
Cancer|February 27, 2008
Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or olderGeorge R Simon, Martine Extermann, Alberto Chiappori, et al.
Molecular Cancer Therapeutics|August 25, 2006
Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trialGeorge R Simon, Richard M Lush, Jana Gump, et al.
JCO Precision Oncology|May 16, 2024
Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non-Small Cell Lung CancerJeanna Wallenta Law, Bela Bapat, Connor Sweetnam, et al.
Cancer Control : Journal of the Moffitt Cancer Center|October 29, 2003
Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institutionGeorge R Simon, John C Ruckdeschel, Charles Williams, et al.
Pageof 8